selected publications
- Inherited Germline Cancer Susceptibility Gene Variants in Individuals with Non-Muscle-Invasive Bladder Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2022 Academic Article GET IT
- Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype. JCO precision oncology. 2022 Academic Article GET IT
- Long-term Outcomes of Local and Metastatic Small Cell Carcinoma of the Urinary Bladder and Genomic Analysis of Patients Treated With Neoadjuvant Chemotherapy. Clinical genitourinary cancer. 2022 Academic Article GET IT
- CD274 (PD-L1) Copy Number Changes (Gain) & Response to Immune Checkpoint Blockade Therapy in Carcinomas of the Urinary Tract. Bladder cancer (Amsterdam, Netherlands). 2022 Academic Article GET IT
-
Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma.
Nature communications.
2022
Academic Article
GET IT
Times cited: 37 - Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell. 2022 Academic Article GET IT
-
Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2022
Academic Article
GET IT
Times cited: 4 -
Pre-clinical activity of the oral DNA-PK inhibitor, peposertib (M3814), combined with radiation in xenograft models of cervical cancer.
Scientific reports.
2022
Academic Article
GET IT
Times cited: 9 - Clinical and Morphologic Characteristics of Fibroblast Growth Factor Receptor Inhibitor-Associated Retinopathy. JAMA ophthalmology. 2021 Academic Article GET IT
- Pretreatment Eosinophil Counts in Patients With Advanced or Metastatic Urothelial Carcinoma Treated With Anti-PD-1/PD-L1 Checkpoint Inhibitors. Journal of immunotherapy (Hagerstown, Md. : 1997). 2021 Academic Article GET IT
- LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade. Science translational medicine. 2021 Academic Article GET IT
-
Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS.
Nature communications.
2021
Academic Article
GET IT
Times cited: 64 - Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non-Muscle-Invasive Bladder Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 Academic Article GET IT
- Clinical and Morphologic Characteristics of Extracellular Signal-Regulated Kinase Inhibitor-Associated Retinopathy. Ophthalmology. Retina. 2021 Academic Article GET IT
-
Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients.
Genome medicine.
2021
Academic Article
GET IT
Times cited: 20 - Pathological and oncological outcomes in patients with sarcomatoid differentiation undergoing cystectomy. BJU international. 2021 Academic Article GET IT
- Developing Precision Medicine for Bladder Cancer. Hematology/oncology clinics of North America. 2021 Information Resource GET IT
-
Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2021
Academic Article
GET IT
Times cited: 23 - OncoTree: A Cancer Classification System for Precision Oncology. JCO clinical cancer informatics. 2021 Academic Article GET IT
- Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma. British journal of cancer. 2021 Academic Article GET IT
-
Genitourinary Medical Oncology Expert Opinion Survey Regarding Treatment Management in the COVID-19 Pandemic.
Clinical genitourinary cancer.
2021
Academic Article
GET IT
Times cited: 2 -
A phase II trial of durvalumab and tremelimumab in metastatic, non-urothelial carcinoma of the urinary tract.
Cancer medicine.
2020
Academic Article
GET IT
Times cited: 10 -
Systemic therapy in bladder preservation.
Urologic oncology.
2020
Information Resource
GET IT
Times cited: 1 - Re: Russell E.N. Becker, Alexa R. Meyer, Aaron Brant, et al. Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.016. European urology. 2020 Article GET IT
-
Germ Cell Tumor Molecular Heterogeneity Revealed Through Analysis of Primary and Metastasis Pairs.
JCO precision oncology.
2020
Academic Article
GET IT
Times cited: 9 -
A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma.
Cancer.
2020
Academic Article
GET IT
Times cited: 16 -
Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma.
European urology.
2020
Academic Article
GET IT
Times cited: 23 -
DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy.
Journal for immunotherapy of cancer.
2020
Academic Article
GET IT
Times cited: 32 -
Emerging biomarkers in urothelial carcinoma: Challenges and opportunities.
Cancer treatment and research communications.
2020
Academic Article
GET IT
Times cited: 8 -
Characterization of on-target adverse events caused by TRK inhibitor therapy.
Annals of oncology : official journal of the European Society for Medical Oncology.
2020
Academic Article
GET IT
Times cited: 35 -
Modeling biological and genetic diversity in upper tract urothelial carcinoma with patient derived xenografts.
Nature communications.
2020
Academic Article
GET IT
Times cited: 29 -
Neoadjuvant Gemcitabine-Cisplatin Plus Radical Cystectomy-Pelvic Lymph Node Dissection for Muscle-invasive Bladder Cancer: A 12-year Experience.
Clinical genitourinary cancer.
2020
Academic Article
GET IT
Times cited: 33 -
Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models.
Scientific reports.
2019
Academic Article
GET IT
Times cited: 31 - The landscape of immunotherapy in metastatic urothelial carcinoma. Current opinion in urology. 2019 Information Resource GET IT
-
PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology: Concordance Among 3 Commonly Used and Commercially Available Antibodies.
The American journal of surgical pathology.
2019
Academic Article
GET IT
Times cited: 55 -
Genomic landscape of inverted urothelial papilloma and urothelial papilloma of the bladder.
The Journal of pathology.
2019
Academic Article
GET IT
Times cited: 35 - Pembrolizumab in the treatment of locally advanced or metastatic urothelial carcinoma: clinical trial evidence and experience. Therapeutic advances in urology. 2019 Information Resource GET IT
-
MRE11 as a Predictive Biomarker of Outcome After Radiation Therapy in Bladder Cancer.
International journal of radiation oncology, biology, physics.
2019
Academic Article
GET IT
Times cited: 23 -
Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma.
Human pathology.
2019
Academic Article
GET IT
Times cited: 27 -
Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2018
Academic Article
GET IT
Times cited: 161 -
Updates on the Genetics and Molecular Subtypes of Urothelial Carcinoma and Select Variants.
Surgical pathology clinics.
2018
Information Resource
GET IT
Times cited: 23 -
Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
European urology.
2018
Academic Article
GET IT
Times cited: 106 -
Low-Grade Serous Ovarian Cancer: Current Treatment Paradigms and Future Directions.
Current treatment options in oncology.
2018
Information Resource
GET IT
Times cited: 10 -
Genome doubling shapes the evolution and prognosis of advanced cancers.
Nature genetics.
2018
Academic Article
GET IT
Times cited: 319 -
ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2018
Academic Article
GET IT
Times cited: 99 -
Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus.
Oncotarget.
2018
Academic Article
GET IT
Times cited: 24 -
Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2018
Academic Article
GET IT
Times cited: 106 -
Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2018
Academic Article
GET IT
Times cited: 380 -
Novel biomarkers in bladder cancer.
Urologic oncology.
2018
Information Resource
GET IT
Times cited: 5 -
Genomic Profile of Urothelial Carcinoma of the Upper Tract from Ureteroscopic Biopsy: Feasibility and Validation Using Matched Radical Nephroureterectomy Specimens.
European urology focus.
2018
Academic Article
GET IT
Times cited: 21 -
HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
Nature.
2018
Academic Article
GET IT
Times cited: 542 -
Genomic Characterization of Upper-Tract Urothelial Carcinoma in Patients With Lynch Syndrome.
JCO precision oncology.
2018
Academic Article
GET IT
Times cited: 37 -
Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer.
Nature communications.
2017
Academic Article
GET IT
Times cited: 90 -
Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2017
Academic Article
GET IT
Times cited: 78 -
Granuloma annulare associated with immune checkpoint inhibitors.
Journal of the European Academy of Dermatology and Venereology : JEADV.
2017
Article
GET IT
Times cited: 20 -
Activating mutation of PDGFRB gene in a rare cardiac undifferentiated intimal sarcoma of the left atrium: a case report.
Oncotarget.
2017
Academic Article
GET IT
Times cited: 11 -
Incidence and Effect of Thromboembolic Events in Radical Cystectomy Patients Undergoing Preoperative Chemotherapy for Muscle-invasive Bladder Cancer.
Clinical genitourinary cancer.
2017
Academic Article
GET IT
Times cited: 9 -
Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.
2017
GET IT
Times cited: 23 -
Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.
European urology.
2017
Academic Article
GET IT
Times cited: 244 -
Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis.
PLoS medicine.
2017
Academic Article
GET IT
Times cited: 236 -
OncoKB: A Precision Oncology Knowledge Base.
JCO precision oncology.
2017
Academic Article
GET IT
Times cited: 1415 -
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.
Nature medicine.
2017
Academic Article
GET IT
Times cited: 2187 -
Next-generation sequencing of urine specimens: A novel platform for genomic analysis in patients with non-muscle-invasive urothelial carcinoma treated with bacille Calmette-Guérin.
Cancer cytopathology.
2017
Academic Article
GET IT
Times cited: 26 -
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel.
Investigational new drugs.
2017
Academic Article
GET IT
Times cited: 10 -
DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2017
Academic Article
GET IT
Times cited: 204 -
ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer.
Cancer research.
2017
Academic Article
GET IT
Times cited: 14 - Editorial Comment. Urology. 2016 Article GET IT
-
Tumor Inhibition by Enzalutamide in a Xenograft Model of Ovarian Cancer.
Cancer investigation.
2016
Academic Article
GET IT
Times cited: 12 -
Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2016
Academic Article
GET IT
Times cited: 133 -
Genomic characterization of response to chemoradiation in urothelial bladder cancer.
Cancer.
2016
Academic Article
GET IT
Times cited: 50 -
Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition.
European urology.
2016
Academic Article
GET IT
Times cited: 65 - Collaborating to Move Research Forward: Proceedings of the 10th Annual Bladder Cancer Think Tank. Bladder cancer (Amsterdam, Netherlands). 2016 Academic Article GET IT
-
Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer.
Nature genetics.
2016
Academic Article
GET IT
Times cited: 131 -
Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma.
The Journal of urology.
2016
Academic Article
GET IT
Times cited: 37 -
Genomic Characterization of Upper Tract Urothelial Carcinoma.
European urology.
2015
Academic Article
GET IT
Times cited: 185 -
Molecular Signature of Response to Pazopanib Salvage Therapy for Urothelial Carcinoma.
Clinical genitourinary cancer.
2015
Academic Article
GET IT
Times cited: 3 -
DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors.
BMC cancer.
2015
Academic Article
GET IT
Times cited: 21 -
The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience.
The oncologist.
2015
Academic Article
GET IT
Times cited: 37 -
Targeted therapy in advanced bladder cancer: what have we learned?.
The Urologic clinics of North America.
2015
Information Resource
GET IT
Times cited: 13 -
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor.
Nature.
2014
Academic Article
GET IT
Times cited: 425 -
Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma.
Cancer discovery.
2014
Academic Article
GET IT
Times cited: 475 -
Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder.
European urology.
2014
Academic Article
GET IT
Times cited: 114 -
Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
2014
Academic Article
GET IT
Times cited: 73 -
Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy.
Cancer discovery.
2014
Academic Article
GET IT
Times cited: 102 -
Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2014
Academic Article
GET IT
Times cited: 71 -
Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology.
Proceedings of the National Academy of Sciences of the United States of America.
2014
Academic Article
GET IT
Times cited: 665 -
Germline single nucleotide polymorphisms associated with response of urothelial carcinoma to platinum-based therapy: the role of the host.
Annals of oncology : official journal of the European Society for Medical Oncology.
2013
Academic Article
GET IT
Times cited: 9 -
Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2013
Academic Article
GET IT
Times cited: 250 -
Phase II study of everolimus in metastatic urothelial cancer.
BJU international.
2013
Academic Article
GET IT
Times cited: 151 -
Specific PPAR gamma agonists may have different effects on cancer incidence.
Annals of oncology : official journal of the European Society for Medical Oncology.
2013
Article
GET IT
Times cited: 4 -
Oncogenic activation of Pak1-dependent pathway of macropinocytosis determines BCG entry into bladder cancer cells.
Cancer research.
2013
Academic Article
GET IT
Times cited: 76 -
BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer.
Cancer.
2012
Academic Article
GET IT
Times cited: 160 -
Genome sequencing identifies a basis for everolimus sensitivity.
Science (New York, N.Y.).
2012
Article
GET IT
Times cited: 587 -
Fibroblast growth factor receptor-3 in urothelial tumorigenesis.
Urologic oncology.
2012
Information Resource
GET IT
Times cited: 43 -
A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors.
Cancer chemotherapy and pharmacology.
2011
Academic Article
GET IT
Times cited: 28 -
Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma.
The Journal of pathology.
2011
Academic Article
GET IT
Times cited: 74 -
Novel strategies for treating relapsed/refractory urothelial carcinoma.
Expert review of anticancer therapy.
2010
Information Resource
GET IT
Times cited: 12